ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Herbst on Immunotherapy Agents in Lung Cancer

Roy S. Herbst, MD, PhD
Published: Thursday, Feb 13, 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the use of immunotherapy agents to treat patients with lung cancer.

Herbst says that immunotherapy agents are showing a 20% response rate across the board in lung cancer, though response rate is not the only factor to consider. When the immune system is targeted, physicians often see slowed tumor growth and durable progression-free survival.

Recent studies of nivolumab, which blocks PD-1, showed a 2-year survival of over 20% of patients with lung cancer. Herbst says physicians are eagerly awaiting results from a phase III trial comparing docetaxel to nivolumab in squamous and non-squamous tumors.
Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the use of immunotherapy agents to treat patients with lung cancer.

Herbst says that immunotherapy agents are showing a 20% response rate across the board in lung cancer, though response rate is not the only factor to consider. When the immune system is targeted, physicians often see slowed tumor growth and durable progression-free survival.

Recent studies of nivolumab, which blocks PD-1, showed a 2-year survival of over 20% of patients with lung cancer. Herbst says physicians are eagerly awaiting results from a phase III trial comparing docetaxel to nivolumab in squamous and non-squamous tumors.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x